Companies · Biotechnology

Pirouette Medical Inc.

PORTSMOUTH · Biotechnology

Diligence memoA one-page analyst read on Pirouette Medical Inc. — recommendation, valuation, rhythm, risks.
$14.0M
Total raised · real
5
Rounds
0.5×
Latest step-up
Top 39%
Sector rank · raised
Series A
Latest stage · inferred · Tue Mar 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Pirouette Medical Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.16× the median modeled value of Series A Biotechnology companies in 2025–2027 (156 peers) — value vs value, same stage and era.
Active
  • Last raise 4 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Pirouette Medical Inc. is one of 4291 Biotechnology companies tracked from PORTSMOUTH. By capital raised it ranks mid-pack (ahead of 62% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
1
Investors (latest)
2026-03-10
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2021-06-21 Raised $1.0M (real) Modeled valuation $27M (est)$1.0M$27MSeed2021Series A · 2021-08-19 Raised $7.0M (real) Modeled valuation $145M (est)$7.0M$145MSeries A2021Series A · 2022-05-31 Raised $2.5M (real) Modeled valuation $37M (est)$2.5M$37MSeries A2022Series A · 2025-03-28 Raised $2.4M (real) Modeled valuation $8.6M (est)$2.4M$8.6MSeries A2025Series A · 2026-03-10 Raised $1.1M (real) Modeled valuation $2.5M (est)$1.1M$2.5MSeries A2026+$7.0M+$2.5M+$2.4M+$1.1MCumulative $14M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2021
Series A$7.0M · 2021
Series A extension$2.5M · 2022
Series A extension$2.4M · 2025
Series A extension$1.1M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$2.5M
Base estimate est.
$1.2M
Conservative case
$3.7M
Upside case
$4.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $26.5M · 2021-06-212021Series A · modeled $145.3M · 2021-08-19Series A · modeled $36.6M · 2022-05-31Series A · modeled $8.6M · 2025-03-28Series A · modeled $2.5M · 2026-03-102026
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.3 yr
Elapsed time used
0.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$3.0M/yr
Capital velocity
5.0 yr
On record since
2021
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$14.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.1M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.5M
Sector median$64.2M

Raised more than 62% of sector peers (real $). Modeled value above 6% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #137 of 156.

This companyCohort peer
$1.0M$10.0M$100.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.5M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.4M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.6M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.1M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.2M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.1M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.8M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.7M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)Pirouette Medical Inc. (this company) Raised $14.0M · modeled $2.5M (est)Pirouette Medical Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.5M3.76×
Edesa Biotech, Inc.Series A$36.9M$58.4M3.75×
4DMedical LtdSeries A$15.0M$50.6M3.25×
Arialys Therapeutics, Inc.Series A$29.1M$49.1M3.15×
Nuclein, LLCSeries A$34.5M$48.3M3.10×
Phantom Neuro Inc.Series A$15.4M$45.7M2.93×
Circulate Health, Inc.Series A$13.0M$43.2M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.1M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.62×
ENDRA Life Sciences Inc.Series A$26.8M$40.8M2.62×
Medici Therapeutics, Inc.Series A$14.8M$39.7M2.55×
Onconetix, Inc.Series A$22.0M$37.7M2.42×
Pirouette Medical Inc. this companySeries A$14.0M$2.5M0.16×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2021-06-21$5.1M$26.5M90%
Series A$7.0M2021-08-19$31.6M$145.3M90%
Series A$2.5M2022-05-31$11.6M$36.6M90%
Series A$2.4M2025-03-28$10.7M$8.6M90%
Series A$1.1M2026-03-10$4.9M$2.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2021-06-21
    • First recorded raise — entered as Seed.
    • 8 investors on this round.
  2. Series A$7.0M2021-08-19
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 6.8× larger than the prior — scaling up.
    • 29 investors on this round.
  3. Series A$2.5M2022-05-31
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 2.7× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  4. Series A$2.4M2025-03-28
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 1 investor on this round.
  5. Series A$1.1M2026-03-10
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2027 ~Q2
Modeled next raise · ~14mo cadence
$1.1M
Modeled next size est.range $1.1M$1.7M
0.5×
Last step-up
$3.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Arunas Chesonis10 other2021-08
MATTHEW KANE3 other2021-06
Joseph Nemmers2 other2021-08
PARINAZ MOTAMEDY2 other2022-05
CONOR CULLINANE2021-06
ELIJAH KAPAS2021-06
Registry & provenance

Pirouette Medical Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1870611
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
GelMEDIX, Inc.BiotechnologySeries A$9.9M$1.6Mnetwork1 shared operator · same sector · same stage
Clerio Vision Inc.BiotechnologySeries A$28.9M$241.9Mnetwork1 shared operator · same sector · same stage
Suono Bio, Inc.BiotechnologySeries A$14.0M$4.0Msame sector · same stage
Immutrix Therapeutics, Inc.BiotechnologySeries A$14.5M$1.4Msame sector · same stage
Luminary Therapeutics, Inc.BiotechnologySeries A$14.5M$4.0Msame sector · same stage
Gregor Diagnostics, Inc.BiotechnologySeries A$14.5M$677Ksame sector · same stage
StemoniX, Inc.BiotechnologySeries A$14.6M$3.6Msame sector · same stage
Elastrin Therapeutics, Inc.BiotechnologySeries A$13.3M$2.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Pi Health Inc.BiotechnologySeries C$421.7M90%
LifeSprout, Inc.BiotechnologySeries B$841.2M84%
Santiste Medical Inc.BiotechnologyPre-Seed$10.3M84%
Pique Therapeutics, Inc.BiotechnologyPre-Seed$47.2M84%
PiroGon, Inc.BiotechnologySeed$25.0M84%
PhenoBiome, Inc.BiotechnologySeed$18.3M84%
Perry Health, Inc.BiotechnologySeries B$416.1M84%
Liquet Medical Inc.BiotechnologySeed$3.9M84%
Frequently asked
How much funding has Pirouette Medical Inc. raised?
Pirouette Medical Inc. has raised approximately $14.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Pirouette Medical Inc.'s estimated valuation?
Provath's modeled valuation for Pirouette Medical Inc. is approximately $2.5M (modeled range $1.2M–$3.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pirouette Medical Inc. at?
Pirouette Medical Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Mar 10.
What does Pirouette Medical Inc. do and where is it based?
Pirouette Medical Inc. operates in the Biotechnology sector, based in PORTSMOUTH.
Explore related

See where Pirouette Medical Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pirouette Medical Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.